Published within
|«
«
|
1
|
2
|
3
|
4
|
5
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
Expert View
|
The EMEA has suspended Acomplia due to the risk of serious psychiatric disorders. The anti-obesity agent had been promised a sure success by numerous analysts, as it addressed indications beyond obesity. However, Acomplia failed to win approval in the US, and just two years after the EU approval its sales have been completely halted, leaving the potentially vast anti-obesity market bare again.
Published By Datamonitor
|
24 Oct 2008 |
|
Expert View
|
Takeda's antidiabetic drug Actos has been suspended in France and Germany following study findings which show that it is associated with an increased risk of bladder cancer. Will other countries follow and how will this impact the oral antidiabetics market?
Published By Datamonitor
|
13 Jun 2011 |
|
CommentWire
|
Ajinomoto has announced its intention to combine its subsidiaries Ajinomoto Pharma and Ajinomoto Medica with its own pharmaceutical arm to establish a new company. The new venture will become operational in April 2010, focusing on digestive and metabolic disorders. However, Datamonitor believes that it has a tough road ahead given the strong competition in these markets.
Published By Datamonitor
|
05 Oct 2009 |
|
Expert View
|
Having announced an end to its co-development and marketing deal with Eli Lilly covering exenatide antidiabetic products, Amylin is now looking for a bigger partner to drive sales of Byetta and the new once-weekly formulation Bydureon. Datamonitor believes that several major pharmaceutical players meet the criteria to become a suitable ally for the company in its ongoing development of exenatide.
Published By Datamonitor
|
11 Nov 2011 |
|
Expert View
|
Lorqess has moved one step closer to approval for the treatment of obesity following a positive review by the FDA advisory committee. The result came as a surprise to some, after the drug was rejected in 2010 due to safety concerns. Despite the good news for Arena Pharmaceuticals, the drug's commercial prospects remain uncertain: the path to launch is unclear, and uptake may be slow.
Published By Datamonitor
|
15 May 2012 |
|
Expert View
|
Well crafted, positive results for AstraZeneca's Brilinta and an unexpected coup for Boehringer Ingelheim's Pradaxa dominated the headlines following this year's European Society of Cardiology's Annual Meeting in Barcelona. Both announcements have a number of important implications for the wider cardiology market, from both therapeutic and commercial perspectives.
Published By Datamonitor
|
03 Sep 2009 |
|
Expert View
|
Autoimmune treatments for type 1 diabetes promise to preserve the body's own insulin production. However, three late-stage candidates - teplizumab, otelixizumab, and Diamyd - have failed to show that they can prevent beta-cell destruction in type 1 patients, confirming Datamonitor's long-held belief that there are many barriers to market entry for these treatments.
Published By Datamonitor
|
03 Jun 2011 |
|
CommentWire
|
Given that BioMarin Pharmaceuticals's Kuvan is potentially the only treatment for the rare genetic metabolic disorder phenylketonuria, Datamonitor believes that Wall Street may be underestimating Kuvan's market potential. Taking into account the high levels of unmet need in this disease, combined with promising late-stage data, Datamonitor predicts US sales of $403 million in 2011 for Kuvan.
Published By Datamonitor
|
25 Oct 2007 |
|
CommentWire
|
Phenoptin, BioMarin's late-stage product candidate, is likely to become the first approved treatment for phenylketonuria, a rare genetic metabolic disorder that affects approximately one in 12,000 births in the US. Given this unmet need, Datamonitor expects Phenoptin to gain US approval in late 2007 with sales forecast to reach $161 million in 2008, almost double that of Wall Street consensus.
Published By Datamonitor
|
12 Oct 2006 |
|
Expert View
|
Pipeline antidiabetic drug Bydureon has overcome another obstacle to approval, with developers Amylin, Eli Lilly, and Alkermes announcing that supratherapeutic doses of the product do not cause a change in heart rhythm by affecting the QT interval. These results pave the way for the resubmission of Bydureon in the US later in 2011.
Published By Datamonitor
|
12 Jul 2011 |
|
|«
«
|
1
|
2
|
3
|
4
|
5
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.